Brief: STADA And Calliditas Partner To Register And Commercialize Specialty Therapy For IgA Nephropathy in Europe

Calliditas Therapeutics AB

21/07/2021 07:45

July 21 (Reuters) - STADA  STAGn.DE :
    * DEAL IS VALUED AT A TOTAL OF EUR 97.5 MILLION, PLUS
ROYALTIES
    * DEAL COVERS EUROPEAN ECONOMIC AREA (EEA) MEMBER STATES,
SWITZERLAND AND THE UK
    * CALLIDITAS THERAPEUTICS AND STADA PARTNER TO REGISTER AND
COMMERCIALIZE SPECIALTY THERAPY FOR IMMUNOGLOBULIN A NEPHROPATHY
IN EUROPE
    * IF APPROVED, PRODUCT COULD BE AVAILABLE TO PATIENTS IN
EUROPE IN
FIRST HALF OF 2022
    * CALLIDITAS IS ALSO ENTITLED TO UP TO ADDITIONAL EUR 77.5
MILLION
IN FUTURE PAYMENTS LINKED TO PRE-DEFINED REGULATORY AND
COMMERCIALIZATION
    * SAYS IT WOULD BE FIRST TREATMENT AUTHORIZED IN EU FOR
CHRONIC
AUTOIMMUNE KIDNEY DISEASE IGAN
    * UNDER TERMS OF AGREEMENT, CALLIDITAS IS ENTITLED RECEIVE
AN
INITIAL UPFRONT PAYMENT OF EUR 20 MILLION UPON SIGNING
    * COMMERCIAL BRAND NAME FOR THERAPY IN EUROPE WILL BE
DETERMINED
AND DISCLOSED AT A LATER DATE

Source text - https://bit.ly/3hVta2k
Further company coverage:  STAGn.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))